Cite
HARVARD Citation
Gonzalez-Cao, M. et al. (2018). Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. Melanoma research. 28 (3), p. . [Online].